Access type

Forgot your password? Click here

DMP_ForgotOK Close


If you are a doctor or a journalist not yet registered at the Dompé reserved areas, click here to fill in the form.



New office inaugurated in Albania

Dompé, an Italian heart and international scope: New office inaugurated in Albania

  • After the office opened in the United States, in New York, the Italian biopharmaceutical group opens its first European branch office in Tirana;
  • This is a yet another step along the path of internationalization that will see a series of new openings in other countries starting from the second half of 2015;
  • Dompé will be present in Albania with its Primary Care products, both with prescription drugs and OTC range.

Milan, 9 July 2015. From today, Albania, a strategic hub for the development and dissemination of pharmaceutical innovation in the Balkans, will be home to a branch office of Dompé, the Italian biopharmaceutical group. Located in the centre of Tirana, it will be inaugurated today on the occasion of the conference “The Albania model, strategic innovation in healthcare as an engine for economic growth”, in the presence of institutions and representatives of the world of healthcare and academia.

The opening speeches were delivered by Sergio Dompé, President of Dompé farmaceutici, Massimo Gaiani, Ambassador of Italy to the Republic of Albania and Edi Rama, Prime Minister of Albania. These were followed by the round table “Innovation, technology, research: strategic assets for the health protection and the competitiveness of the country, and for the development of a new Balkan region”, with the participation of Milva Ekonomi, Albanian Deputy Minister of Health, Artan Gaçi, member of the Commission for Production Activities, Trade and Environment of the Albanian Parliament, Luciano D’Alfonso, President of the Abruzzo Region and Eugenio Aringhieri, CEO of Dompé farmaceutici.

“We are proud to announce the opening of the Albanian branch office, a moment that is part of a broader growth project of the company, which sees internationalisation as one of its pillars,” - says Sergio Dompé, President of the company. Albania has succeeded in creating suitable conditions for attracting investment and skills, making the health sector one of the strategic assets for the country’s growth. The prospect of providing our therapeutic solutions goes hand in hand with the consolidated experience in scientific information. The goal is to establish ourselves as a responsible partner in the Albanian healthcare sector, building a positive collaboration and a constant dialogue with stakeholders.”.

Through its ability to attract resources and skills in the most dynamic sectors, as is the case of healthcare, Albania is today a key hub in the Balkans. Its focus on the future and attention to sustainability are generating a healthcare model that aims to meet the needs of citizens in innovative ways. In this context Dompé has chosen to invest in the country.

“The Tirana branch office is a strategic choice in the company’s growth toward the markets of the Balkan region and Eastern Europe, once again testifying to the quality of our product range, for the safeguard of the health needs of patients,” explains Eugenio Aringhieri, CEO of Dompé farmaceutici. “Albania is an important partner for Italy, especially in a field such as healthcare, in which there is a tangible potential to attract international investment. Dompé fits into this context with the awareness that it is able to actively contribute to the renewal process in progress that aims at the improvement of services and solutions for the well-being of people."

The first objective of the Albanian branch office of the Dompé Group is to develop the company’s commercial operations. It is the first step in a strategy that provides for the gradual consolidation of the Italian pharmaceutical group efforts in Albania and in the Balkans. In the initial phase, Dompé will be present with the product range of the Primary Care line, in both the OTC and prescription drugs areas. In the first two years, moreover, the launch of new medicinal products is planned, in view of a progressive broadening of the product range.